Galectin Therapeutics GALT, the leading developer of therapeutics
that target galectin proteins to treat fibrosis and cancer, today announced
that the American Chemical Society (ACS), as part of its ACS Symposium Series,
has published online the proceedings from the galectin-focused symposium
hosted by Galectin Therapeutics, Galectins and Disease Implications for
Targeted Therapeutics. The book is edited by Dr. Anatole Klyosov, Chief
Scientist at Galectin, and Dr. Peter G. Traber, Chief Executive Officer and
Chief Medical Officer of Galectin.
“The reviews in this compendium by international experts provide a clear
picture of the emerging importance of galectin proteins in a wide variety of
diseases,” said Dr. Traber. “As evidenced by this symposium, there is great
interest in continuing to expand the therapeutic applications for
galectin-targeted proteins and we are thrilled that Galectin Therapeutics is
at the forefront of that translational medicine, with compounds in development
for the treatment of liver fibrosis, including non-alcoholic steatohepatitis
(NASH) liver disease, and advanced metastatic melanoma.”
This peer reviewed compendium focuses on galectins in disease and was inspired
by topics discussed at the international symposium hosted by Galectin
Therapeutics, “Galectin Function and Therapeutics”, which took place in Boston
in September, 2012. This comprehensive guide, organized as a series of
mini-reviews by leading experts on galectins and their biomedical and
therapeutic applications, provides current understandings of galectin proteins
and their role in inflammatory pathophysiology, as well as their potential
utility in drug design of targeted therapeutics. It is designed to help
chemical scientists, biologists, oncologists and gastroenterologists to
understand the important role that galectins play in disease and that
carbohydrate-based drugs may have in treatment of liver fibrosis, cancer and
other inflammatory diseases.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in